Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Greene

Showing results (1-10 of 438) with videos related to

Pageof 44
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|April 19, 2021
Randomized Controlled Trials 6: Determining the Sample Size and Power for Clinical Trials and Cohort StudiesTom Greene
Methods in Molecular Biology (Clifton, N.J.)|February 20, 2015
Randomized controlled trials 5: Determining the sample size and power for clinical trials and cohort studiesTom Greene
Journal of the American Society of Nephrology : JASN|October 15, 2025
Considerations for Using eGFR Slope as an End Point in Clinical TrialsTom Greene,
Journal of the American Society of Nephrology : JASN|October 30, 2025
Integrating Information across End Points in CKD Clinical TrialsTom Greene
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 3, 2009
Randomized and observational studies in nephrology: how strong is the evidence?Tom Greene
Contributions to Nephrology|May 7, 2005
What did we learn from the HEMO Study? Implications of secondary analysesTom Greene
The International Journal of Biostatistics|August 2, 2013
A weighting analogue to pair matching in propensity score analysisLiang Li, Tom Greene
Clinical Trials (London, England)|October 21, 2011
Statistical analysis and design for estimating accuracy in clinical-center classification of cause-specific clinical events in clinical trialsGuofen Yan, Tom Greene
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 26, 2017
From Static to Dynamic Risk Prediction: Time Is EverythingTom Greene, Liang Li
Biometrics|November 1, 2007
Varying coefficients model with measurement errorLiang Li, Tom Greene
Pageof 44

Showing results (1-10 of 438) with videos related to

Sort By:
Pageof 44
Methods in Molecular Biology (Clifton, N.J.)|April 19, 2021
Randomized Controlled Trials 6: Determining the Sample Size and Power for Clinical Trials and Cohort StudiesTom Greene
Methods in Molecular Biology (Clifton, N.J.)|February 20, 2015
Randomized controlled trials 5: Determining the sample size and power for clinical trials and cohort studiesTom Greene
Journal of the American Society of Nephrology : JASN|October 15, 2025
Considerations for Using eGFR Slope as an End Point in Clinical TrialsTom Greene,
Journal of the American Society of Nephrology : JASN|October 30, 2025
Integrating Information across End Points in CKD Clinical TrialsTom Greene
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 3, 2009
Randomized and observational studies in nephrology: how strong is the evidence?Tom Greene
Contributions to Nephrology|May 7, 2005
What did we learn from the HEMO Study? Implications of secondary analysesTom Greene
The International Journal of Biostatistics|August 2, 2013
A weighting analogue to pair matching in propensity score analysisLiang Li, Tom Greene
Clinical Trials (London, England)|October 21, 2011
Statistical analysis and design for estimating accuracy in clinical-center classification of cause-specific clinical events in clinical trialsGuofen Yan, Tom Greene
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 26, 2017
From Static to Dynamic Risk Prediction: Time Is EverythingTom Greene, Liang Li
Biometrics|November 1, 2007
Varying coefficients model with measurement errorLiang Li, Tom Greene
Pageof 44